Kolton Gustafson

Kolton Gustafson

Managing DirectorAdvisory

Kolton Gustafson assists clients in evaluating the impact of federal health policy developments on their business priorities and policy engagement strategies. He uses his experience in government payment systems and reimbursement and his familiarity with provider perspectives to support engagements in cell and gene therapy, drug pricing, physician payment, Medicare reimbursement, and healthcare reform. Prior to joining Avalere, Kolton was a senior analyst at Mass General Brigham where he monitored Medicare and Medicaid policy changes to assess financial impact on network hospitals. He also tracked the rule-making process for federal/state payment systems and drafted feedback to CMS on reimbursement and quality proposals. Prior to this, he was a research assistant at the Dana-Farber Cancer Institute in the Department of Cell Therapies, working with bone marrow transplant patients and collaborating on patient education efforts. He has also worked on health policy and communications for the American College of Physicians. Kolton has an MPH in health policy from the Harvard T. H. Chan School of Public Health and a BA in political science from the George Washington University.

Latest content authored by Kolton Gustafson

Drug pricing and affordability

Legislative proposals aim to modify the 340B program

Drug pricing and affordability

Maximum fair price effectuation and the Standard Default Refund Amount: The possibility of average sales price spirals in competitive drug classes

Drug pricing and affordability

340B payment proposal would increase payment to most hospitals

Drug pricing and affordability

Effectuation and Standard Default Refund Amount: The dilemma of competitive drug classes

Drug pricing and affordability

340B purchases surge past $100 billion

Drug pricing and affordability

Negotiated Part B drug effectuation proposals: Four Standard Default Refund Amount approaches and key trade-offs

Coverage and payment

Part B negotiated drug prices: How Medicare Advantage plans should prepare

Cell and gene therapy

Inpatient hospital changes proposed for cell therapy

Drug pricing and affordability

How MFN pricing in Part B may affect beneficiary OOP costs

Drug pricing and affordability

340B purchase data highlights continued program growth